Premature structural failure of Trifecta bioprosthesis in midterm follow-up: A single-centre study

Abstract Background A cluster of aortic bioprosthetic valve failures, most of which were Trifecta bioprostheses, was observed in our institution. This study was performed to assess if the cluster represents a significant failure of this valve model or if there is a selection bias that can explain the failure of these valves. Methods This retrospective study evaluated all bioprosthetic aortic valve replacement operations performed between 2011-2016 inclusive in our center. We compared the performance of Trifecta with that of Perimount, Perimount Magna Ease and Mitroflow bioprostheses. In addition, we analyzed patient-related and valve-related risk factors for early failure in the failed valves. Results A total of 2807 bioprosthetic aortic valve replacements were performed. Of these, 836 were Trifecta valves, 1031 Perimount, 449 Perimount Magna Ease and 351 Mitroflow valves. Twenty-four Trifecta valves suffered premature structural failure significantly higher than Perimount or Perimount Magna Ease (no failure, p Conclusions The Trifecta bioprosthesis has an increased incidence of early structural valve failure, which is significantly higher than that of Perimount, Perimount Magna Ease or Mitroflow. No patient-related or valve-related cause for the failure could be identified.